Ipatasertib combined with abiraterone in PTEN null prostate cancer improved progression-free survival in a randomized phase II study of patients with mCRPC, providing clinical evidence of reciprocal activation between the Akt and AR pathways. These data revive the rationale for targeting PTEN loss in prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Sep 11 [Epub ahead of print]
Tian Zhang, Daniel J George, Andrew J Armstrong
Department of Medicine, Duke University., Departments of Medicine and Surgery, Duke University, Duke Cancer Institute., Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery, Duke Cancer Institute .